A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
about
Methotrexate for Inflammatory Bowel Diseases - New DevelopmentsUse of Methotrexate in the Treatment of Inflammatory Bowel Diseases.Efficacy and safety of granulocyte, monocyte/macrophage adsorptive in pediatric ulcerative colitisLong-term safety of immunomodulators in pediatric inflammatory diseases.Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease.Adalimumab for the treatment of pediatric Crohn's disease.Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach.Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy.Risk assessment in Crohn's disease.Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience.Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.Re: American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease.Therapeutic role of methotrexate in pediatric Crohn's disease.Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.
P2860
Q34518393-E670EF16-5B89-4C4D-A0B1-9101371C7C42Q36372720-ADFC81D9-1D61-4DC6-B845-E9529B31E328Q36859998-0A1C3E30-21C7-44C5-96BE-44917F4E2E3CQ38232338-55D0D7D1-57CC-4FD0-9A0B-9A948C1BE46CQ38365848-EC652244-E82B-4409-8FBC-A2C8D6924996Q38554433-E815F839-5DEA-47D8-BAD9-731AE07A0895Q38610162-087D261F-8D40-4B73-92BB-703423B8AE95Q39834984-AA01EC0F-F97C-4382-AB6B-24A7D2CF8A0FQ40237363-1809706E-B421-4B6A-B16E-E0A493354156Q41909743-B36AFD99-360E-4DCF-9B9D-64A435FF60E3Q42293326-252EA5F4-6182-4191-8F16-7387D03EEA31Q47160953-BA63DE16-B0EE-4DEB-ACCC-7C1961CE7614Q47198925-07ABE98D-E4D6-462C-AD34-DD37C8661C24Q48250204-8D6B4119-34D0-4A27-AF2A-15D3924FCF3AQ49193405-8AA306AA-D7AB-4DB8-8D07-28B8C4F0B425Q50025325-18B1B580-7459-472C-A1D4-14625CC30E9EQ54449204-41120BC0-EE65-45A3-A31E-D95B48757394
P2860
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@en
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@nl
type
label
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@en
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@nl
prefLabel
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@en
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@nl
P2093
P2860
P1476
A 10-year, single tertiary car ...... ic inflammatory bowel disease.
@en
P2093
Elaheh Vahabnezhad
Marla C Dubinsky
Shervin Rabizadeh
P2860
P304
P356
10.1097/MIB.0000000000000003
P577
2014-04-01T00:00:00Z